| CD26 + CD4 + T cell counts and attack risk in interferon-treated multiple sclerosis. | |
| | |
MedLine Citation:
|
PMID: 16320722 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Biomarkers that allow the identification of patients with multiple sclerosis (MS) with an insufficient response to immunomodulatory treatment would be desirable, as currently available treatments are only incompletely efficacious. Previous studies have shown that the expression of CD25, CD26 and CCR5 on T cells is altered in patients with active MS. We studied the expression of these molecules by flow cytometry in patients followed for six months during immunomodulatory treatment. In interferon (IFN)-beta-treated patients, we found that the hazard ratio for developing an attack was 28 in patients with CD26 + CD4 + T cell counts above median, and this risk was independent of the risk conferred by neutralizing anti-IFN-beta antibodies. CD26 + CD4 + T cell counts may identify patients with MS at increased risk of attack during treatment with IFN-beta. |
| | |
Authors:
|
F Sellebjerg; C Ross; N Koch-Henriksen; P Soelberg S?rensen; J L Frederiksen; K Bendtzen; T L S?rensen |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Multiple sclerosis (Houndmills, Basingstoke, England) Volume: 11 ISSN: 1352-4585 ISO Abbreviation: Mult. Scler. Publication Date: 2005 Dec |
Date Detail:
|
Created Date: 2005-12-02 Completed Date: 2006-02-03 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9509185 Medline TA: Mult Scler Country: England |
Other Details:
|
Languages: eng Pagination: 641-5 Citation Subset: IM |
Affiliation:
|
The MS Clinic, Copenhagen University Hospital, Glostrup, Denmark. sellebjerg@dadlnet.dk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adjuvants, Immunologic
/
administration & dosage* Adult Antigens, CD26 / metabolism Antigens, CD4 / metabolism Biological Markers CD4 Lymphocyte Count CD4-Positive T-Lymphocytes / cytology*, immunology, metabolism CD8-Positive T-Lymphocytes / cytology, immunology, metabolism Female Flow Cytometry Humans Interferon-beta / administration & dosage* Male Middle Aged Multiple Sclerosis, Relapsing-Remitting / drug therapy*, epidemiology, immunology* Proportional Hazards Models Receptors, CCR5 / metabolism Receptors, Interleukin-2 / metabolism Risk Factors |
| Chemical | |
Reg. No./Substance:
|
0/Adjuvants, Immunologic; 0/Antigens, CD4; 0/Biological Markers; 0/Receptors, CCR5; 0/Receptors, Interleukin-2; 145155-23-3/interferon beta-1b; 145258-61-3/interferon beta 1a; 77238-31-4/Interferon-beta; EC 3.4.14.5/Antigens, CD26 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Multiple sclerosis management for low-income minorities.
Next Document: Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-re...